Advancing Oligonucleotide & Peptide Therapeutics from Clinical R&D to Manufacturing in Asia
23 - 24 March 2027
Sands Expo & Convention Centre, Singapore
Part of Biopharma APAC Confex 2027
Co-located Events
.png)
.png)
.png)
.png)
Sponsors & Media Partners
Special thanks to our event partners, without whom we would not be able to provide this networking, learning, and collaborating platform.
EXHIBITOR
Media & Publicity
2027 SPEAKERS
Andy Xian Zheng, PhD
CEO
Byterna Therapeutics
Singapore
Alap Gandhi
Country Medical Director
GSK
Malaysia
Bin Xia Yang
Director
Hengrui R&D Centre
Singapore
Prof. Rakesh Veedu
Professor/Co-Founder & MD/CEO
Murdoch University/ ProGenis Pharmaceuticals
Australia
Wonil Kim
CSO
Aston Sci
South Korea
Dr. Pratik Dave
Senior Scientist
Roche
Switzerland
Dr. Bharti Prafulla Deshmukh
HOD of RND Peptide Genric
Hovid Bhd
Malaysia
Stephen Lin
Vice General Manager
ExoOne Bio
Taiwan
CONFERENCE AGENDA
Day 1
Tuesday, 23 March 2027
8:50
IMAPAC’s Opening Remarks
8:55
Chairman’s Welcome Address
Asia’s Frontier in Oligonucleotide Therapeutics
9:00
Leadership Panel: From Manufacturing Powerhouse to Innovation Leader — Can Asia Lead the Next Generation of Oligonucleotide Therapeutics?
- Positioning APAC as a global hub for oligonucleotide discovery, development and commercialization
- Building stronger links between biotech innovation, pharma, academia, CDMOs and investors
- Moving Asia beyond manufacturing toward globally originated therapeutic pipelines
- Identifying the capabilities and partnerships required to compete globally
PANELISTS
Bin Xia Yang
Director, Hengrui R&D Centre
9:50
Engineering the Next Generation of ASO & siRNA Therapeutics: Potency, Precision & Durability
- Advancing ASO and siRNA design for improved potency and selectivity
- Optimising chemical modifications to enhance stability and therapeutic performance
- Balancing efficacy, safety, durability and dosing frequency
- Accelerating candidate selection from discovery into clinical development
Reserved for Solution Provider
10:05
Beyond the Liver: Breaking the Extrahepatic Delivery Barrier for Oligonucleotide Therapeutics
- Expanding delivery beyond hepatic targets into CNS, muscle, immune cells and other tissues
- Advancing receptor- and ligand-mediated targeting approaches
- Overcoming endosomal escape and intracellular delivery barriers
- Translating promising delivery technologies from preclinical models into patients
10:30
Morning Tea, Exhibition Viewing & 1-1 Networking
Peptide Therapeutics 2.0 — Beyond GLP-1
11:15
Beyond GLP-1: Where Will the Next Generation of Peptide Blockbusters Come From?
- Expanding peptide therapeutics into oncology, immunology, CNS and rare diseases
- Identifying opportunities beyond metabolic and obesity indications
- Advancing multi-agonist, multispecific and multifunctional peptide platforms
- Differentiating peptides from antibodies and small molecules
11:40
Cyclic & Constrained Peptides: Unlocking Intracellular and Previously Undruggable Targets
- Using cyclic and constrained architectures to improve affinity and selectivity
- Accessing intracellular targets traditionally considered undruggable
- Improving proteolytic stability, permeability and pharmacokinetics
- Translating complex peptide scaffolds into developable drug candidates
Reserved for Solution Provider
11:55
Engineering Long-Acting Peptides: Extending Half-Life Without Compromising Potency & Safety
- Designing peptides for extended systemic exposure and reduced dosing frequency
- Evaluating lipidation, conjugation, depot and sustained-release strategies
- Balancing half-life extension with potency, stability and safety
- Developing more convenient and patient-friendly dosing strategies
12:20
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Breaking the Delivery Barrier — From Oral Peptides to Precision Oligos
2:05
Panel Discussion: Oral Peptide Delivery: Can We Finally Break the Bioavailability Barrier
- Overcoming enzymatic degradation and gastrointestinal barriers
- Evaluating permeation enhancers and novel formulation technologies
- Improving oral bioavailability while maintaining safety
- Translating promising oral peptide technologies into commercially viable therapies
2:35
Precision Peptide Delivery: Engineering Tissue-Specific & Intracellular
- Engineering peptides to overcome membrane and physiological barriers
- Advancing receptor-mediated and ligand-directed tissue targeting
- Optimising biodistribution while reducing off-target exposure
- Translating preclinical delivery performance into clinically meaningful exposure
Reserved for Solution Provider
2:50
Next-Generation Delivery Platforms for RNA & Oligonucleotide Therapeutics
- Comparing emerging delivery technologies beyond conventional approaches
- Exploring extracellular vesicles and other next-generation carriers
- Improving cargo loading, cellular uptake and tissue specificity
- Addressing scalability, manufacturability and clinical translation
Stephen Lin
Vice General Manager, ExoOne Bio
3:25
Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Networking
Convergence — Peptide–Oligonucleotide Conjugates & Hybrid Modalities
4:10
Beyond GalNAc: Peptide–Oligonucleotide Conjugates for the Next Frontier of Targeted
- Identifying where peptide-enabled targeting can outperform existing delivery technologies
- Expanding oligonucleotide delivery into difficult tissues and cell types
- Comparing cell-penetrating, receptor-targeting and tissue-specific peptides
- Determining which conjugate platforms offer the strongest clinical and commercial potential
4:35
Conjugate by Design: Engineering Peptide–Linker–Oligonucleotide Architectures for Maximum Therapeutic Performance
- Optimising peptide, linker and oligonucleotide architecture
- Balancing potency, selectivity, stability, PK/PD and intracellular release
- Selecting conjugation strategies based on target tissue and mechanism
- Using computational and AI-enabled approaches to accelerate candidate optimisation
Reserved for Solution Provider
4:55
From Chemistry to Clinic: Scaling Peptide–Oligonucleotide Conjugates for Commercial Manufacturing
- Scaling synthesis and conjugation while maintaining yield and purity
- Controlling conjugation-related heterogeneity and critical quality attributes
- Overcoming purification challenges for increasingly complex molecules
- Building scalable CMC strategies from clinical development to commercial supply
5:20
Chairman’s Closing Remarks
5:30
End of Day 1 Conference
6:00
Cocktails & Networking
6:30
Asia-Pacific Biopharma Excellence Awards 2027 Gala Dinner
CONFERENCE AGENDA
Day 2
Wednesday, 24th March 2027
8:50
IMAPAC’s Opening Remarks
8:55
Chairman’s Welcome Address
From Asia to Global Clinical Development & Regulatory Approval
9:00
Oligos:
From Asia to Global Approval: Navigating Regulatory & CMC Pathways for Oligonucleotide Therapeutics
- Addressing oligonucleotide-specific regulatory and CMC expectations
- Managing sequence-related impurities, chemical modifications and comparability
- Aligning development strategies across the US, Europe, China, Japan, Korea and Singapore
- Designing APAC programmes capable of supporting global regulatory submissions
9:25
From First-in-Human to Global Development: De-Risking Clinical Translation from Asia
- Translating preclinical PK/PD, biodistribution and toxicology into clinical dose selection
- Designing efficient first-in-human and early-phase trials
- Selecting biomarkers and endpoints to demonstrate proof of mechanism
- Using APAC clinical development to accelerate progression into global programmes
Reserved for Solution Provider
9:40
Peptides:
From Asia to Global Approval: Regulatory & CMC Strategies for Next-Generation Peptide Therapeutics
- Addressing regulatory requirements for conventional, cyclic, modified and complex peptides
- Establishing specifications around purity, degradation, stability and product quality
- Managing manufacturing changes and comparability throughout development
- Building regulatory strategies that enable Asia-developed therapies to enter global markets
10:05
From Accelerated Approval to Global Launch: Late-Stage Development & Lifecycle Strategy for Oligos and Peptides
- Translating clinical evidence into patient access
- Building evidence strategies for innovative therapeutics
- Navigating regulatory and healthcare stakeholder requirements
- Moving therapies from development toward real-world adoption
Alap Gandhi
Country Medical Director, GSK
10:30
Morning Break, Exhibition Viewing & 1-1 Networking
Oligonucleotide Manufacturing — From Synthesis to Commercial Scale
11:15
From Clinical Supply to Commercial Manufacturing: Building Scalable Oligonucleotide Processes
- Moving from development-scale synthesis into robust GMP manufacturing
- Establishing scalable processes for increasing commercial deman
- Managing technology transfer between internal facilities and CDMOs
- Building supply strategies that support clinical and commercial growth
11:40
Scaling Oligonucleotide Synthesis: Yield, Purity, Solvent Reduction & Commercial Throughput
- Improving coupling efficiency, cycle times and overall synthesis yield
- Reducing solvent and reagent consumption at commercial scale
- Managing sequence length and complexity as pipelines evolve
- Increasing throughput without compromising product quality
Reserved for Solution Provider
11:55
Greener & Smarter Oligo Manufacturing: Can New Technologies Transform the Economics of Synthesis?
- Reducing solvent intensity, waste and environmental footprint
- Evaluating alternative and hybrid synthesis technologies
- Applying automation, digitalisation and process monitoring
- Balancing sustainability improvements with COGS and manufacturing performance
12:20
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Peptide Manufacturing — Scale, Cost & GMP Readiness
2:05
Scaling Peptide Therapeutics for Commercial Manufacturing: From Solid-Phase Synthesis to GMP & Regulatory Readiness
- Developing robust peptide processes from bench scale to cGMP manufacturing
- Managing process optimisation, scale-up and manufacturing transfer
- Integrating analytical method development with peptide process development
- Preparing peptide products for regulatory and DMF requirements across the US and Europe
Dr. Bharti Prafulla Deshmukh
HOD of RND Peptide Genric, Hovid Bhd
2:30
Reducing the Cost of Peptide Manufacturing at Commercial Scale: SPPS, LPPS & Process Intensification
- Reducing resin, solvent and reagent consumption
- Comparing SPPS, LPPS and hybrid manufacturing approaches
- Improving coupling efficiency, yield and throughput
- Identifying opportunities to significantly reduce commercial COGS
Reserved for Solution Provider
2:45
Purification: The Hidden Bottleneck in Commercial Peptide Manufacturing
- Tackling purification challenges as peptide complexity increases
- Improving recovery and purity without sacrificing manufacturing yield
- Optimising chromatography and alternative purification strategies
- Reducing purification time, solvent consumption and cost at commercial scale
3:10
From Bench to GMP: Scaling Complex Peptide Therapeutics Without Losing Quality
- Translating laboratory processes into robust GMP manufacturing
- Establishing CQAs and process controls during scale-up
- Managing technology transfer and manufacturing comparability
- Integrating analytical development with peptide process development
3:35
Afternoon Tea, Exhibition Viewing & 1-1 Networking
Closing Roundtable Discussion: Bridging the Gaps: Practical Solutions for Manufacturing, Trials, Logistics & Drug Development in Asia
4:20
Biologics Manufacturing Asia
- Scaling Smarter: How Can We Drive Process Intensification Without Compromising Quality?
- Future-Proofing Biomanufacturing: What Does a Truly Agile, Digital-First Facility Look Like in Asia?
- CMC Excellence in a Complex World: What Frameworks Enable Seamless Quality, Analytics, and Compliance?
ADC Asia Congress
- Cracking the Code on ADC Stability: What Formulation Innovations Are Showing Real Results?
- From Bench to Bedside: What’s Missing in Translating Preclinical ADC Wins to Clinical Success?
- Strategic Licensing in the Asian ADC Market: Unlocking Growth Opportunities
BioSupply Chain Asia
- Building a Smart, Resilient Cold Chain: What Technologies Are Actually Reducing Risk Today?
- Greener Logistics: How Can APAC Balance Efficiency and Sustainability in Biopharma Supply Chains?
- Intelligent Supply Chains: How Are AI, Blockchain, and Automation Rewiring Biopharma Operations?
Clinical Trial Asia
- Winning Over Patients: What Engagement Strategies Are Reshaping Clinical Trial Participation in Asia?
- Trial Tech & Trust: How Can We Ensure Data Integrity While Embracing AI in Clinical Research?
Oligos & Peptides Asia
- Beyond Purity: Tackling Oligonucleotide Impurities & Analytical Challenges
- Beyond Purity: Managing Peptide Aggregation, Degradation & Stability
5:20
Chairman’s Closing Remarks
5:30
End of Day 2 Conference
By Profile
By Job Title
By Geography
20%
Europe, USA & Rest of World
25%
China & Taiwan
20%
Japan & South Korea
15%
Australia & India
20%
Hong Kong & South East Asia
20%
Europe, USA & Rest of World
25%
China & Taiwan
20%
Japan & South Korea
15%
Australia & India
20%
Hong Kong & South East Asia
Our Past Partners
.png)
%20(1)%20(1).png)
%20Logo.png)
